Your browser doesn't support javascript.
loading
Hyper-Dependence on NHEJ Enables Synergy between DNA-PK Inhibitors and Low-Dose Doxorubicin in Leiomyosarcoma.
Marino-Enriquez, Adrian; Novotny, Jan Philipp; Gulhan, Doga C; Klooster, Isabella; Tran, Antuan V; Kasbo, Macy; Lundberg, Meijun Z; Ou, Wen-Bin; Tao, Derrick L; Pilco-Janeta, Daniel F; Mao, Victor Y; Zenke, Frank T; Leeper, Brittaney A; Gokhale, Prafulla C; Cowley, Glenn S; Baker, Laurence H; Ballman, Karla V; Root, David E; Albers, Joachim; Park, Peter J; George, Suzanne; Fletcher, Jonathan A.
Afiliación
  • Marino-Enriquez A; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Novotny JP; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Gulhan DC; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Klooster I; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts.
  • Tran AV; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Kasbo M; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts.
  • Lundberg MZ; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Ou WB; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Tao DL; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Pilco-Janeta DF; Zhejiang Provincial Key Laboratory of Silkworm Bioreactor and Biomedicine, Zhejiang Sci-Tech University, Hangzhou, China.
  • Mao VY; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Zenke FT; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Leeper BA; Sarcoma Translational Research Laboratory, Vall d'Hebron Institute of Oncology, Autonomous University of Barcelona, Barcelona, Spain.
  • Gokhale PC; Department of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts.
  • Cowley GS; Research Unit Oncology, The Healthcare Business of Merck KGaA, Darmstadt, Germany.
  • Baker LH; Experimental Therapeutics Core and the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ballman KV; Experimental Therapeutics Core and the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Root DE; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Albers J; Michigan Medicine, University of Michigan, Ann Arbor, Michigan.
  • Park PJ; Division of Biostatistics and Epidemiology, Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, New York.
  • George S; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Fletcher JA; Research Unit Oncology, The Healthcare Business of Merck KGaA, Darmstadt, Germany.
Clin Cancer Res ; 29(24): 5128-5139, 2023 12 15.
Article en En | MEDLINE | ID: mdl-37773632
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leiomiosarcoma Tipo de estudio: Prognostic_studies Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Leiomiosarcoma Tipo de estudio: Prognostic_studies Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article